Our Story

In 2019, we learned that our son Charlie has SLC6A1, an ultra-rare genetic disorder that causes seizures, autism, developmental delays, and significant behavioral challenges. With fewer than 500 known cases worldwide and no approved treatments, the diagnosis was devastating — but it also pushed us into action.

Shortly after, we partnered with another SLC6A1 family and helped assemble a world-class scientific team. Together, we have developed a breakthrough gene therapy that targets the root cause of this disease. And in September of 2025, the first child, Maxwell, became the first in the world to receive this therapy, proving that real hope is no longer out of reach.

Now our mission is urgent: we must fund this treatment so more children — including Charlie — can access it. Every donation accelerates manufacturing, clinical progress, and expands availability for the kids still waiting.

Charlie is bright, funny, curious, and full of life. 

He fights every day — and with your help, he won’t have to fight forever.